Bio-Rad Laboratories (NYSE:BIO.B) continues to mark new achievements. While the stock reached a new 52-week high, its short interest increased by 18.8%. Analysts unanimously recommend it as a promising asset, backed by its outperform rating by the Royal Bank of Canada. Despite recent losses leading to a 58% decrease in market value, the stock remains an attractive opportunity. Its prices managed to bounce back, giving a strong counter indicator. Investors continue to show interest: Contravisory Investment Management and Wedge Capital Management took significant positions; Diversified Trust Co and Principal Financial Group Inc also increased their stakes. There have been mixed outcomes in recent quarterly results. Q3 surpassed earnings and revenue estimates; however, a forecast cut due to weak biotech demand cast a shadow. The company's leadership underwent some changes; it welcomed a new President and COO, while Dara Grantham Wright resigned as Executive VP and President. As per recent analyses, the company's return on capital employed (ROCE) remained a concern. However, the future growth potential and anticipated earnings keep Bio-Rad in a positive light. Despite recent turbulence, the long-term stance remains bullish.
Bio-Rad Laboratories Stocks News Analytics from Thu, 21 Jun 2018 02:34:36 GMT to Fri, 24 Jan 2025 20:35:19 GMT -
Rating 8
- Innovation 2
- Rumor 4
